留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

慢性乙型肝炎的抗病毒研究进展

操跃,  钱其军

downloadPDF
文章导航 > 药学实践与服务  > 2015 >  33(6): 561-565
操跃, 钱其军. 慢性乙型肝炎的抗病毒研究进展[J]. 药学实践与服务, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
引用本文: 操跃, 钱其军. 慢性乙型肝炎的抗病毒研究进展[J]. 药学实践与服务, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
shu
CAO Yue, QIAN Qijun. Progress in study of antiviral effect of chronic hepatitis B[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
Citation: CAO Yue, QIAN Qijun. Progress in study of antiviral effect of chronic hepatitis B[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
shu

慢性乙型肝炎的抗病毒研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.022
  • 1.

    福建医科大学第一临床医学院, 福建 福州 350108;第二军医大学附属东方肝胆外科医院肿瘤生物治疗科、病毒基因治疗实验室, 上海 200438

  • 2.

    第二军医大学附属东方肝胆外科医院肿瘤生物治疗科、病毒基因治疗实验室, 上海 200438

Progress in study of antiviral effect of chronic hepatitis B

  • 1.

    First Clinical Medical College, Fujian Medical University, Fuzhou 350108, China;Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China

  • 2.

    Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China

  • 摘要: 慢性乙型肝炎是由乙型肝炎病毒(hepatitis B virus,HBV)引起的全球性传染病,HBV感染是我国肝硬化、原发性肝癌的重要原因。目前,干扰素类与核苷(酸)类似物抗病毒药物已广泛应用于临床,在一定程度上抑制了病毒的复制并控制了疾病的发展,但仍未从根本上清除病毒;各种治疗性疫苗在抗HBV方面也取得了一定疗效,但临床效果不佳。目前不少研究结果表明,生物免疫治疗可以成功清除体内的HBV,从而为乙肝的治疗带来新的希望。
    Abstract: Chronic hepatitis B is a worldwide infectious diseases caused by hepatitis B virus (HBV). HBV infection is an important reason for liver cirrhosis and liver cancer in our country. Currently, the interferon and nucleoside analogs antiviral drugs (nucleotides) is widely used in clinical practice. These drugs inhibit the replication of the virus and disease development to a certain extent, but not fundamentally eliminate the virus. Various therapeutic vaccines have also made certain curative effect in anti HBV, but the effect is not perfect clinically. At present, many research Results demonstrate that biological immunotherapy can successfully eliminate HBV virus in the body, therefore it has brought a new hope for the treatment of hepatitis B.
  • [1] Robinson WS, Lutwick LI, et al. The virus of hepatitis, type B(fist of two parts)[J]. N Engl J Med,1976,295:1168-1175.
    [2] Ito K, Qin Y, Guarnieri M, et al.Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein andrescue by a novel glycosylation site[J]. Virol,2010,84:12850-12861.
    [3] Shin D, Kim SI, Kim M, et al.Efficient inhibition of hepatitis B virus replication by small interfering RNAs targeted to the viral X gene inmice[J]. Virus Res,2006,119:146-153.
    [4] Roingeard P,Lu SL,Sureau C,et al.Immunocytochemical and electron microscopic study of hepatitis B virus antigen and complete particle production in hepatitis B virus DNA transfected HepG2 cells[J].Hepatology,1990,11(2):277-285.
    [5] Kanto T,Inoue M,Miyatake H,et al.Reduced number impaired ability of myeloid and plasmacytoid dendritic cell polarize T helper cells in chronic hepatitis C virus infection[J].J Infect Dis,2004,190(11):1919-1926.
    [6] van der Molen RG,Sprengers D,Binda RS,et al .Function impairment of myeloid and plasmacytoid dendritic cells tients with chronic hepatitis B[J].Hepatology,2004,40(3):738-746.
    [7] Stoop JN,van der Molen RG,Baan CC,et al.Regulatory cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection[J].Hepatology,2005,41(4):771-778.
    [8] Xu D,Fu J,Jin L,et al.Circulating and liver resident CD4,CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B[J].J Immunol, 2006,177(1):739-747.
    [9] Sandalova E,Laccabue D,Boni C,et al.Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells[J].Gastroenterology,2012,143(1):78-87.
    [10] Zhang Z,Zhang S,Zou Z,et al.Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients[J].Hepatology,2011,53(1):73-85.
    [11] Fattovich G, Stroffolini T, Zagni I,et al.Hepatocellular carcinoma in cirrhosis: incidence and risk factors[J]. Gastroenterology,2004,127(5 suppl 1): S35-S50.
    [12] Janssen HL, van Zonneveld M, Senturk H,et al.Pegylated interferon-alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B:arandomised trial[J].Lancet, 2005,365(9454):123-129.
    [13] Lau GK, Piratvisuth T, Luo KX,et al.Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B[J].N Engl J Med, 2005,352(26):2682-2695.
    [14] Dienstag JL.Drug therapy: hepatitis B virus infection[J].N Engl J Med,2008,359:1486-500.
    [15] Gish RG, Lok AS, Chang TT,et al. Entecavir therapy for up to 96 weeks inpatients with HBeAg-positive chronic hepatitis B[J]. Gastroenterology,2007,133: 1437-1444.
    [16] Zoutendijk R, Reijnders JG, Zoulim F,et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis[J]. Gut,2013,62: 760-765.
    [17] Barbaro G, Zechini F, Pellicelli AM, et al. Long-term efficacy of interferon-alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B.An Italian multicenter, randomized trial[J]. Hepatol,2001,35:406-411.
    [18] Petersen J, Ratziu V, Buti M,et al.Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study[J]. Hepatol,2012,56(3): 520-526.
    [19] Michel ML, Tiollais P. Hepatitis B vaccines: protective efficacy and the rapeutic potential[J].Pathol Biol,2010, 58(4):288-295.
    [20] Sheppard CW, Samar EP,Finely L,et al.Hepatitis B virus infection: epidemiol and vaccination[J].Epidemiol Rev,2006,28:112-125.
    [21] Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan[J]. JAMA,1996, 276(11):906-908.
    [22] 贺学新.非核苷类似药物在慢性乙肝治疗中的应用[J].现代医药卫生,2008,24(5):717- 718.
    [23] Betaneourt AA.Phase I clinical trial in healthy adults of a nasalvaccine candidate containing recombinant hepatitis B surface and core antigens[J].Int J Infect Dis,2007,11(5):394-401.
    [24] Hu ZB, Liu Y, Zhai XJ, et al.New loci associated with chronic hepatitis B virus infection in Han Chinese[J].Nat Genet,2013,45(12):1499-1503.
    [25] Rehermann B.IntrahepaticT cells in Hepatitis B:viral control versus liver cell injury[J].J Exp Med,2000,191:1263-1268.
    [26] Bertoletti A,Ferrari C.Kinetics of the immune response during HBV and HCV infection[J].Hepatology,2003,38(1):4-13.
    [27] Shiina S, Fujino H, Uta Y, et al.Relationship of HBsAg subtypes with HBeAg/anti-HBe status and chronic liver disease. Part I: analysis of 1744 HBsAg carriers[J].Am J Gastroenterol, 1991,86(7):866-871.
    [28] Chen X, Tang Y, Zhang Y,et al.Peietal Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo[J].Lab Invest, 2014,94(5):478-490.
    [29] Pan XW, Ding HG, Zhou XY,et al.Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A*33:03 in peripheral blood mononuclear cells from patients and transgenic mice[J].Biochem Biophys Res Commun,2014,449:135-140.
    [30] Ito H, Hoshi M, Ohtaki H,et al. Ability of IDO to attenuate liver injury in a-galactosylceramide-induced hepatitis model[J].J Immunol,2010,185(8):4554-4560.
    [31] Ito H, Seishima M. Regulation of the induction and function of cytotoxic T lymphocytes by natural killer T cell[J]. Biomed Biotechnol,2010,10:641-757.
    [32] Kim D, Hung CF, Wu TC,et al. DNA vaccine with a-galactosylceramide at primephase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells[J]. Vaccine,2010, 28:7297-305.
    [33] Ito H, Ando K, Ishikawa T, et al. Role of Va14+ NKT cells in the development of hepatitis B virus-specific CTL: activation of Va14+ NKT cells promotes the breakage of CTL tolerance[J]. Int Immunol,2008,20:869-879.
    [34] Akbar SM, Chen S, Al-Mahtab M, et al. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccinesin a murine model of chronic hepatitis B: HBcAg is a candidate for atherapeutic vaccine against hepatitis B virus[J]. Antiviral Res,2012,96:59-64.
    [35] Chen W, Shi M, Shi F, et al. HBcAg-pulsed dendritic cell vaccine induces Th1 polarization and production of hepatitis B virus-specific cytotoxic T lymphocytes[J]. Hepatol Res,2009,39:355-365.
    [36] Chen X, Liu H, Tang Z, et al. The modification of Tapasin enhances cytotoxic T lymphocyte activity of intracellular delivered CTL epitopes via cytoplasmic transduction peptide[J]. Acta Biochim Biophys Sin(ABBS,Shanghai), 2013,45(3):203-212.
  • [1] 陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾.  基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 1-8. doi: 10.12206/j.issn.2097-2024.202401073
    [2] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
    [3] 丁华敏, 郭羽晨, 秦春霞, 宋志兵, 孙莉莉.  消风止痒颗粒通过降低白三烯水平对小鼠特应性皮炎急性瘙痒的治疗作用研究 . 药学实践与服务, 2024, 42(5): 211-216. doi: 10.12206/j.issn.2097-2024.202306031
    [4] 陈春娟, 郑志新, 李骊.  平喘方联合孟鲁司特钠治疗儿童支气管哮喘患者的临床疗效观察 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202405035
    [5] 戴菲菲, 傅翔, 陈琼年, 俞苏纯.  上海某二级医院革兰阴性菌流行特征的回顾性分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202305005
    [6] 桂明珠, 李静, 李志玲.  儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
    [7] 冯志惠, 邓仪卿, 叶冰, 安培, 张宏, 张海军.  雀梅藤石油醚提取物诱导三阴性乳腺癌细胞凋亡的实验研究 . 药学实践与服务, 2024, 42(6): 253-259. doi: 10.12206/j.issn.2097-2024.202311055
    [8] 陈莹, 许子华, 胡北, 崔亚玲, 高欢, 吴琼.  通便灵胶囊治疗便秘的药效与机制研究 . 药学实践与服务, 2024, 42(): 1-7. doi: 10.12206/j.issn.2097-2024.202404008
    [9] 王耀振, 徐灿, 吕顺莉, 田泾, 张东炜.  钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
    [10] 张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英.  二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
    [11] 宋泽成, 陈林林, 鲁仁义, 刘梦肖, 王彦.  脓毒症治疗的研究进展 . 药学实践与服务, 2024, 42(11): 1-5. doi: 10.12206/j.issn.2097-2024.202405059
    [12] 顾佳钰, 胡馨儿, 王晓飞, 张颖, 张海, 曹岩.  侧流免疫层析定量检测方法的研究进展 . 药学实践与服务, 2024, 42(7): 273-277, 284. doi: 10.12206/j.issn.2097-2024.202307037
    [13] 迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛.  负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
    [14] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
    [15] 孙丹倪, 黄勇, 张嘉宝, 王培.  代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
    [16] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [17] 杨嘉宁, 赵一颖, 肖伟.  七味脂肝方对非酒精性脂肪性肝炎动物模型的药效学评价 . 药学实践与服务, 2024, 42(9): 389-398. doi: 10.12206/j.issn.2097-2024.202404096
    [18] 景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞.  黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
    [19] 马兹芬, 许维恒, 金煜翔, 薛磊.  食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
    [20] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3202
  • HTML全文浏览量:  316
  • PDF下载量:  336
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-02-10
  • 修回日期:  2015-07-13

慢性乙型肝炎的抗病毒研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.022
  • 1. 福建医科大学第一临床医学院, 福建 福州 350108;第二军医大学附属东方肝胆外科医院肿瘤生物治疗科、病毒基因治疗实验室, 上海 200438
  • 2. 第二军医大学附属东方肝胆外科医院肿瘤生物治疗科、病毒基因治疗实验室, 上海 200438
  • 收稿日期: 2015-02-10
  • 修回日期: 2015-07-13

摘要: 慢性乙型肝炎是由乙型肝炎病毒(hepatitis B virus,HBV)引起的全球性传染病,HBV感染是我国肝硬化、原发性肝癌的重要原因。目前,干扰素类与核苷(酸)类似物抗病毒药物已广泛应用于临床,在一定程度上抑制了病毒的复制并控制了疾病的发展,但仍未从根本上清除病毒;各种治疗性疫苗在抗HBV方面也取得了一定疗效,但临床效果不佳。目前不少研究结果表明,生物免疫治疗可以成功清除体内的HBV,从而为乙肝的治疗带来新的希望。

English Abstract

操跃, 钱其军. 慢性乙型肝炎的抗病毒研究进展[J]. 药学实践与服务, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
引用本文: 操跃, 钱其军. 慢性乙型肝炎的抗病毒研究进展[J]. 药学实践与服务, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
shu
CAO Yue, QIAN Qijun. Progress in study of antiviral effect of chronic hepatitis B[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
Citation: CAO Yue, QIAN Qijun. Progress in study of antiviral effect of chronic hepatitis B[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
shu

    全文HTML

参考文献 (36)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计